A-240610.0の非対称合成は,キラリティ移転による軸性キラルビアリルの新しいアトロプセレクティブアプローチによる
Yi-Yin Ku1, Tim Grieme, Prasad Raje
1D-R450, Process Chemistry, Global Pharmaceutical Research and Development, Abbott Laboratories, North Chicago, Illinois 60064-4000, USA. yiyin.ku@abbott.com
Journal of the American Chemical Society
|April 19, 2002
まとめ
研究者は,キラリティの移転を用いたアトロポセレクティブバイアリル合成のための新しい方法を開発しました. この技術は効率的に単一のアトロピゾーマーを生成し,A-240610.0.0の非対称合成を可能にします.
科学分野:
- 有機化学 オーガニック・ケミストリー
- アシンメトリック・シンセシス
背景:
- 軸性キラルバイアリルは,医薬品や材料における重要な構造モチーフである.
- ステレオ選択的合成のための効率的な方法の開発は,依然として課題です.
研究 の 目的:
- 軸性キラルバイアリルを準備するための新しいアトロポセレクティブ方法を開発する.
- 特定のアトロピゾーメの合成において,高いステレオ選択性と収量を達成するために.
- この方法論をA-240610.0.0.の非対称合成に適用する.
主な方法:
- 二次アルコールのステレオジェニックセンターからビアリル軸へのキラリティの移転.
- 地域選択的分子内シリル群移動.
- 標的アトロピソメアの分離と特徴付け.
主要な成果:
- 新しいアトロポセレクティブビアリル製剤の成功開発方法.
- 単一のアトロピゾーマー (2) を 85% の収量と 99:1 のダイアステレオ選択性で作る.
- A-240610.0の効率的な非対称合成が達成されました.
結論:
- 開発された方法は,高いステレオコントロールを持つアトロピソマーへの効率的な経路を提供します.
- このアプローチは,A-240610.0.0.のような複雑な分子の合成を容易にする.
- キラリティ移転戦略は,非対称合成における貴重なツールです.
さらに関連する動画
関連する概念動画
Gene Conversion
Other than maintaining genome stability via DNA repair, homologous recombination plays an important role in diversifying the genome. In fact, the recombination of sequences forms the molecular basis of genomic evolution. Random and non-random permutations of genomic sequences create a library of new amalgamated sequences. These newly formed genomes can determine the fitness and survival of cells. In bacteria, homologous and non-homologous types of recombination lead to the evolution of new...
Disubstituted Cyclohexanes: cis-trans Isomerism
Depending upon the different spatial orientation of the substituents, the disubstituted cycloalkanes exhibit two types of stereoisomers. The cis isomers have the substituents on the same side of the ring, whereas the trans isomers have the substituents on the opposite sides. These stereoisomers exhibit different physical properties and cannot be interconverted without breaking the carbon-carbon bonds.
In cyclohexane, the substituents can occupy different positions generating distinct isomers.
In cyclohexane, the substituents can occupy different positions generating distinct isomers.
SN2 Reaction: Stereochemistry
In an SN2 reaction, the nucleophilic attack on the substrate and departure of the leaving group occurs simultaneously through a transition state. As the nucleophile approaches the substrate from the back-side, the configuration of the substrate carbon changes from tetrahedral to trigonal bipyramidal and then back to tetrahedral, leading to an inversion in the configuration of the product.
If the substrate is an achiral molecule at the α-carbon, the inversion of configuration is not observed.
If the substrate is an achiral molecule at the α-carbon, the inversion of configuration is not observed.
[3,3] Sigmatropic Rearrangement of 1,5-Dienes: Cope Rearrangement
The Cope rearrangement is classified as a [3,3] sigmatropic shift in 1,5-dienes, leading to a more stable, isomeric 1,5-diene. The reaction involves a concerted movement of six electrons, four from two π bonds and two from a σ bond, via an energetically favorable chair-like transition state.
Nucleophilic Aromatic Substitution: Addition–Elimination (SNAr)
Nucleophilic substitution in aromatic compounds is feasible in substrates bearing strong electron-withdrawing substituents positioned ortho or para to the leaving group. The reaction proceeds via two steps: the addition of the nucleophile and the elimination of the leaving group.
The reaction begins with an attack of the nucleophile on the carbon that holds the leaving group. This results in the delocalization of the π electrons over the ring carbons. The resonance interaction between the...
The reaction begins with an attack of the nucleophile on the carbon that holds the leaving group. This results in the delocalization of the π electrons over the ring carbons. The resonance interaction between the...
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...


